Global Markets Direct’s, ‘Vichem Chemie Research Ltd. – Product Pipeline Review -2015′, provides an overview of the Vichem Chemie Research Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vichem Chemie Research Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides brief overview of Vichem Chemie Research Ltd. including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of Vichem Chemie Research Ltd.’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
• Latest news and deals relating to the Vichem Chemie Research Ltd.’s pipeline products

Reasons to buy

• Evaluate Vichem Chemie Research Ltd.’s strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of Vichem Chemie Research Ltd. in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the Vichem Chemie Research Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Vichem Chemie Research Ltd. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vichem Chemie Research Ltd.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of Vichem Chemie Research Ltd. and identify potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Vichem Chemie Research Ltd. Snapshot 6
Vichem Chemie Research Ltd. Overview 6
Key Information 6
Key Facts 6
Vichem Chemie Research Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Vichem Chemie Research Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Vichem Chemie Research Ltd. - Pipeline Products Glance 14
Vichem Chemie Research Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Vichem Chemie Research Ltd. - Drug Profiles 17
Small Molecule for Central Nervous System and Autoimmune Disorders 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecules to Inhibit CDK9 for HIV-1 Infection 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
VID-45110 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BBH-7 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BTP-15 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule to Antagonize VEGFR2 for Undisclosed Indication 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small molecule to Inhibit FLT3 for Acute Myeloid Leukemia 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule to Inhibit PLK1 for Cancer and Bacterial Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecule to Inhibit ROCK2 for Undisclosed Indication 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecules for Chronic Heart Failure 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules for Escherichia Coli Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Multiple Myeloma 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Antagonize HGFR and EGFR for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Antagonize Pan FGFR for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Antagonize PDGFR-beta for Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit Aurora A Kinase for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit Aurora B Kinase for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit CDK4 for Oncology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
VCC-405567 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VCC-668662 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Vichem Chemie Research Ltd. - Pipeline Analysis 38
Vichem Chemie Research Ltd. - Pipeline Products by Target 38
Vichem Chemie Research Ltd. - Pipeline Products by Molecule Type 40
Vichem Chemie Research Ltd. - Pipeline Products by Mechanism of Action 41
Vichem Chemie Research Ltd. - Dormant Projects 43
Vichem Chemie Research Ltd. - Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Vichem Chemie Research Ltd., Key Information 6
Vichem Chemie Research Ltd., Key Facts 6
Vichem Chemie Research Ltd. - Pipeline by Indication, 2015 8
Vichem Chemie Research Ltd. - Pipeline by Stage of Development, 2015 10
Vichem Chemie Research Ltd. - Monotherapy Products in Pipeline, 2015 11
Vichem Chemie Research Ltd. - Partnered Products in Pipeline, 2015 12
Vichem Chemie Research Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 13
Vichem Chemie Research Ltd. - Preclinical, 2015 14
Vichem Chemie Research Ltd. - Discovery, 2015 15
Vichem Chemie Research Ltd. - Pipeline by Target, 2015 39
Vichem Chemie Research Ltd. - Pipeline by Molecule Type, 2015 40
Vichem Chemie Research Ltd. - Pipeline Products by Mechanism of Action, 2015 42
Vichem Chemie Research Ltd. - Dormant Developmental Projects,2015 43

List of Figures

Vichem Chemie Research Ltd. - Pipeline by Top 10 Indication, 2015 8
Vichem Chemie Research Ltd. - Pipeline by Stage of Development, 2015 10
Vichem Chemie Research Ltd. - Monotherapy Products in Pipeline, 2015 11
Vichem Chemie Research Ltd. - Pipeline by Top 10 Target, 2015 38
Vichem Chemie Research Ltd. - Pipeline by Top 10 Molecule Type, 2015 40
Vichem Chemie Research Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 41